ECSP16078289A - CROMENO Y 1,1a,2,7b–TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS - Google Patents

CROMENO Y 1,1a,2,7b–TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS

Info

Publication number
ECSP16078289A
ECSP16078289A ECIEPI201678289A ECPI201678289A ECSP16078289A EC SP16078289 A ECSP16078289 A EC SP16078289A EC IEPI201678289 A ECIEPI201678289 A EC IEPI201678289A EC PI201678289 A ECPI201678289 A EC PI201678289A EC SP16078289 A ECSP16078289 A EC SP16078289A
Authority
EC
Ecuador
Prior art keywords
chrome
pyridopyrazinediones
tetrahydrocyclopropa
novel
compounds
Prior art date
Application number
ECIEPI201678289A
Other languages
English (en)
Inventor
John Michael Humphrey
Danica Antonia Rankic
Gregory Wayne Kauffman
Patrick Robert Verhoest
Martin Youngjin Pettersson
Ende Christopher William Am
Douglas Scott Johnson
Antonia Friederike Stepan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52815058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP16078289(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP16078289A publication Critical patent/ECSP16078289A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los compuestos y las sales farmacéuticamente aceptables de los mismos se describen, en donde los compuestos tienen la estructura de la Fórmula I en X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, y y z son como se define en la especificación. Las composiciones farmacéuticas correspondientes, métodos de tratamiento, métodos de síntesis, e intermediarios también se describen.
ECIEPI201678289A 2014-04-01 2016-09-30 CROMENO Y 1,1a,2,7b–TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS ECSP16078289A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461973436P 2014-04-01 2014-04-01

Publications (1)

Publication Number Publication Date
ECSP16078289A true ECSP16078289A (es) 2017-02-24

Family

ID=52815058

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201678289A ECSP16078289A (es) 2014-04-01 2016-09-30 CROMENO Y 1,1a,2,7b–TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS

Country Status (29)

Country Link
US (2) US20150274721A1 (es)
EP (1) EP3126361B1 (es)
JP (1) JP6643247B2 (es)
KR (1) KR101886945B1 (es)
CN (1) CN106211770B (es)
AP (1) AP2016009465A0 (es)
AR (1) AR099874A1 (es)
AU (1) AU2015242330B2 (es)
BR (1) BR112016022519A8 (es)
CA (1) CA2944308A1 (es)
CL (1) CL2016002422A1 (es)
CR (1) CR20160454A (es)
CU (1) CU20160140A7 (es)
DK (1) DK3126361T3 (es)
DO (1) DOP2016000266A (es)
EA (1) EA031419B1 (es)
EC (1) ECSP16078289A (es)
ES (1) ES2759277T3 (es)
IL (1) IL248154B (es)
MD (1) MD20160102A2 (es)
MX (1) MX369074B (es)
NI (1) NI201600149A (es)
PE (1) PE20161364A1 (es)
PH (1) PH12016501864A1 (es)
SG (1) SG11201607465UA (es)
TW (1) TWI568733B (es)
UY (1) UY36054A (es)
WO (1) WO2015150957A1 (es)
ZA (1) ZA201606252B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
MX368391B (es) * 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
CN106580997B (zh) * 2016-12-09 2018-01-19 张田 一种治疗先兆流产的药物组合物
MX390370B (es) 2016-12-16 2025-03-20 Pipeline Therapeutics Inc Metodos para tratar la sinaptopatia coclear
AU2019339777B2 (en) * 2018-09-12 2022-09-01 Novartis Ag Antiviral pyridopyrazinedione compounds
CN110907542A (zh) * 2018-09-17 2020-03-24 复旦大学 一种液质联用检测唾液中司来吉兰及其代谢物的方法
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020179859A1 (ja) 2019-03-06 2020-09-10 第一三共株式会社 ピロロピラゾール誘導体
AU2020353055B2 (en) 2019-09-26 2024-03-07 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
AU2023364628A1 (en) 2022-10-18 2025-04-03 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
EP2006303A1 (en) 1997-04-09 2008-12-24 Intellect Neurosciences, Inc. Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
WO2002042429A2 (en) 2000-11-03 2002-05-30 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
BR0308109A (pt) * 2002-02-28 2005-01-04 Sanofi Aventis Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arila
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
MXPA05003621A (es) 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
MXPA05013770A (es) 2003-06-19 2006-03-08 Pfizer Prod Inc Antagonista de neuroquinina 1.
US20070031416A1 (en) 2003-09-09 2007-02-08 Takeda Pharmaceutical Company Limited Use of antibody
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
EP1720847A1 (en) 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
JP2008543923A (ja) 2005-06-22 2008-12-04 ファイザー・プロダクツ・インク ヒスタミン−３受容体アンタゴニスト
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
RS20080484A (sr) 2006-04-21 2009-07-15 Pfizer Products Inc., PIRIDIN[3,4-b] PIRAZINONI
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
EP2124933B1 (en) 2007-01-22 2012-10-17 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
EP2355659A4 (en) * 2008-10-23 2012-10-10 Merck Sharp & Dohme Fused Hetereocyclic M1 Receptor Positive Allosmatic Modulators
EP2691393B1 (en) * 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
US9181245B2 (en) * 2012-05-16 2015-11-10 Janssen Pharmaceuticals, Inc. Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease
UA110688C2 (uk) * 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CA2891755C (en) * 2013-01-17 2021-10-26 Janssen Pharmaceutica Nv Substituted pyrido-piperazinone derivatives as gamma secretase modulators
ES2742078T3 (es) * 2013-10-04 2020-02-13 Pfizer Piridonas bicíclicas novedosas como moduladores de gamma-secretasa

Also Published As

Publication number Publication date
CU20160140A7 (es) 2017-02-02
PH12016501864A1 (en) 2016-12-19
BR112016022519A8 (pt) 2018-03-06
MX369074B (es) 2019-10-28
TWI568733B (zh) 2017-02-01
CN106211770B (zh) 2018-02-06
ES2759277T3 (es) 2020-05-08
UY36054A (es) 2015-10-30
CR20160454A (es) 2016-12-06
EA201600619A1 (ru) 2017-03-31
KR20160137635A (ko) 2016-11-30
AU2015242330A1 (en) 2016-09-22
HK1231481A1 (zh) 2017-12-22
EP3126361B1 (en) 2019-11-06
DOP2016000266A (es) 2016-11-15
DK3126361T3 (da) 2020-01-02
WO2015150957A1 (en) 2015-10-08
BR112016022519A2 (pt) 2017-08-15
AR099874A1 (es) 2016-08-24
PE20161364A1 (es) 2016-12-25
MX2016012904A (es) 2016-12-07
JP2017512803A (ja) 2017-05-25
US20150274721A1 (en) 2015-10-01
AU2015242330B2 (en) 2017-08-17
SG11201607465UA (en) 2016-10-28
KR101886945B1 (ko) 2018-08-08
AP2016009465A0 (en) 2016-09-30
TW201540716A (zh) 2015-11-01
IL248154B (en) 2020-09-30
IL248154A0 (en) 2016-11-30
MD20160102A2 (ro) 2017-04-30
EP3126361A1 (en) 2017-02-08
CA2944308A1 (en) 2015-10-08
CN106211770A (zh) 2016-12-07
CL2016002422A1 (es) 2017-02-03
US20170166566A1 (en) 2017-06-15
EA031419B1 (ru) 2018-12-28
NI201600149A (es) 2016-11-18
ZA201606252B (en) 2018-05-30
JP6643247B2 (ja) 2020-02-12

Similar Documents

Publication Publication Date Title
ECSP16078289A (es) CROMENO Y 1,1a,2,7b–TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
CY1125436T1 (el) Αναστολεις dna-pk
CY1123756T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
CY1119487T1 (el) Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα
CL2016003293A1 (es) Inhibidores de mnk y método relacionado al mismo
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
CO2017012994A2 (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
UY36073A (es) ?2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS?.
UY35039A (es) ?piridinonas bicíclicas novedosas?
UY34542A (es) ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
ECSP17007336A (es) Compuestos de imidazopiridazina
UY35182A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[ 3,4-d][1,3]TIAZIN-2-AMINA? .
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
UY36546A (es) “ciclopropabenzofuranil-piridopirazindionas novedosas”.
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
UY33976A (es) Derivados de pirazolo-pirimidina.
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
CY1120608T1 (el) Φαρμακευτικως δραστικες ενωσεις
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
UY34082A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona,preparación de los mismos y uso terapéutico de los mismos
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные
EA201400786A1 (ru) Карбоциклические нуклеозиды, их фармацевтическое применение и композиции